-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KiWHmjdAPB7xQfgpbAKrVaRAgkfgqlEqD49TDpgnTNHRl39fpbqO0n2SvLCnP3fh Tz4G/R4oEoDLKt7klLcqog== 0001144204-06-020333.txt : 20060515 0001144204-06-020333.hdr.sgml : 20060515 20060515140402 ACCESSION NUMBER: 0001144204-06-020333 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060331 FILED AS OF DATE: 20060515 DATE AS OF CHANGE: 20060515 EFFECTIVENESS DATE: 20060515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 06839386 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v043009_bakerbros-13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2006 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. May 12, 2006 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 66 ----------- Form 13F Information Table Entry Value: 830,422 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 9,606 601,104 SH SOLE 601,104 Adolor Corp. COM 00724X102 26,518 1,114,197 SH SOLE 1,114,197 Allos Therapeutics Inc. COM 019777101 15,403 4,388,380 SH SOLE 4,388,380 Altus Pharmaceuticals Inc. COM 02216N105 5,096 232,381 SH SOLE 232,381 Amylin Pharmaceuticals Inc. COM 032346108 86,843 1,774,112 SH SOLE 1,774,112 Anadys Pharmaceuticals Inc. COM 03252Q408 5,642 350,237 SH SOLE 350,237 Anormed Inc. COM 035910108 62,518 9,411,500 SH SOLE 9,411,500 Arena Pharmaceuticals Inc. COM 040047102 5,426 299,619 SH SOLE 299,619 Array Biopharma Inc. COM 04269X105 2,465 269,696 SH SOLE 269,696 Atherogenics Inc. COM 047439104 817 50,036 SH SOLE 50,036 Autoimmune Inc. COM 052776101 40 26,100 SH SOLE 26,100 Biocryst Pharmaceuticals Inc. COM 09058V103 32,054 1,774,838 SH SOLE 1,774,838 Biomarin Pharmaceutical Inc. COM 09061G101 511 38,100 SH SOLE 38,100 Cerus Corp. COM 157085101 3,852 450,000 SH SOLE 450,000 Coley Pharmaceutical Group Inc. COM 19388P106 8,306 548,266 SH SOLE 548,266 Columbia Labaratories Inc. COM 197779101 4,306 866,336 SH SOLE 866,336 Corcept Therapeutics Inc. COM 218352102 524 100,200 SH SOLE 100,200 Cotherix Inc. COM 22163T103 795 87,000 SH SOLE 87,000 Critical Therapeutics Inc. COM 22674T105 2,054 403,531 SH SOLE 403,531 Cubist Pharmaceuticals Inc. COM 229678107 7,426 323,293 SH SOLE 323,293 Curis Inc. COM 231269101 64 26,800 SH SOLE 26,800 Cytokinetics Inc. COM 23282W100 717 98,300 SH SOLE 98,300 Genomic Health Inc. COM 37244C101 10,343 997,402 SH SOLE 997,402 GTX Inc. COM 40052B108 162 14,800 SH SOLE 14,800 Halozyme Therapeutics Inc. COM 40637H109 1,725 500,000 SH SOLE 500,000 Icagen Inc. COM 45104P104 476 57,315 SH SOLE 57,315 Idera Pharmaceuticals Inc. COM 45168K108 11,455 18,181,820 SH SOLE 18,181,820 Incyte Corp. COM 45337C102 19,951 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 14,967 2,061,586 SH SOLE 2,061,586 Insmed Inc. COM 457669208 163 83,817 SH SOLE 83,817 Intermune Inc. COM 45884X103 11,514 621,058 SH SOLE 621,058 Intrabiotics Pharmaceuticals COM 46116T506 4,137 1,199,234 SH SOLE 1,199,234 Ithaka Acquisition Corporation COM 465707206 347 65,000 SH SOLE 65,000 Ligand Pharmaceuticals Inc. CL B 53220K207 493 38,357 SH SOLE 38,357 Medarex Inc. COM 583916101 11,796 892,303 SH SOLE 892,303 Metabasis Therapeutics Inc. COM 59101M105 19,892 2,188,354 SH SOLE 2,188,354 Monogram Biosciences Inc. COM 60975U108 858 466,419 SH SOLE 466,419 Myriad Genetics Inc. COM 62855J104 34,186 1,310,325 SH SOLE 1,310,325 Neopharm Inc. COM 640919106 7,509 898,221 SH SOLE 898,221 Neose Technologies Inc. COM 640522108 1,563 576,923 SH SOLE 576,923 Neurogen Corp. COM 64124E106 32,968 5,325,999 SH SOLE 5,325,999 Nuvelo Inc. COM 67072M301 22,650 1,271,067 SH SOLE 1,271,067 Onyx Pharmaceuticals Inc. COM 683399109 19,298 734,866 SH SOLE 734,866 Pharmacyclics Inc. COM 716933106 981 213,219 SH SOLE 213,219 Pozen Inc. COM 73941U102 10,146 607,544 SH SOLE 607,544 Renovis Inc. COM 759885106 6,396 300,000 SH SOLE 300,000 Seattle Genetics Inc. COM 812578102 6,166 1,194,927 SH SOLE 1,194,927 Senomyx Inc. COM 81724Q107 687 41,715 SH SOLE 41,715 Spectrum Pharmaceuticals Inc. COM 84763A108 219 46,700 SH SOLE 46,700 Sunesis Pharmaceuticals Inc. COM 867328502 7,924 1,127,214 SH SOLE 1,127,214 Telik Inc. COM 87959M109 267 13,800 SH SOLE 13,800 Theravance Inc. COM 88338T104 11,521 410,869 SH SOLE 410,869 Trimeris Inc. COM 896263100 48,668 3,602,369 SH SOLE 3,602,369 Vertex Pharmaceuticals Inc. COM 92532F100 41,532 1,135,064 SH SOLE 1,135,064 Viropharma Inc. COM 928241108 49,068 3,863,629 SH SOLE 3,863,629 Xcyte Therapies Inc. PFD CV EXCH 98389F408 621 95,500 SH SOLE 95,500 Xenoport Inc. COM 98411C100 6,271 276,970 SH SOLE 276,970 YM Biosciences Inc. COM 984238105 302 54,876 SH SOLE 54,876 Zymogenetics Inc. COM 98985T109 17,134 792,514 SH SOLE 792,514 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 48,114 38,300,000 PRN SOLE 38,300,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 13,680 9,000,000 PRN SOLE 9,000,000 Biomarin Pharmaceuticals Notes 2.5% 3/29/2013 CONV BONDS 09061GAC5 14,630 14,000,000 PRN SOLE 14,000,000 Decode Genetics Notes 3.5% 4/15/2011 CONV BONDS 243586AB0 2,584 3,000,000 PRN SOLE 3,000,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 15,533 19,000,000 PRN SOLE 19,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 5,693 6,000,000 PRN SOLE 6,000,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 14,850 13,500,000 PRN SOLE 13,500,000
-----END PRIVACY-ENHANCED MESSAGE-----